UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
(Rule
14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☐
Filed by a Party other than the Registrant ☒
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☒ | Soliciting Material Under § 240.14a-12 |
NOVAVAX, INC. |
(Name of Registrant as Specified In Its Charter)
|
|
SHAH CAPITAL MANAGEMENT, INC.
SHAH CAPITAL OPPORTUNITY FUND LP
HIMANSHU H. SHAH
|
(Name of Persons(s) Filing Proxy Statement, if other than the Registrant)
|
Payment of Filing Fee (Check all boxes that apply):
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Shah Capital Management, Inc.
and the other participants named herein (collectively, “Shah Capital”) have filed a preliminary proxy statement and accompanying
GOLD universal proxy card with the Securities and Exchange Commission to be used to solicit votes AGAINST the election of
Richard H. Douglas, Margaret G. McGlynn and David Mott to the Board of Directors of Novavax, Inc., a Delaware corporation (“Novavax”
or the “Company”) at the Company’s 2024 upcoming annual meeting of stockholders (the “Annual Meeting”) and
AGAINST the approval of certain of the Company’s other proposals to be considered by stockholders at the Annual Meeting.
On March 6, 2024, Shah Capital
issued the following press release:
Shah Capital Launches Campaign Urging Stockholders
to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting
Highlights Novavax’s Massive Untapped Value
That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined
Stockholder Value
Calls for Fresh Perspectives in the Boardroom to
Restore Investor Confidence in the Company
Files Preliminary Proxy and Urges Stockholders to
Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three of the Company’s Other Proposals
at the Annual Meeting
Raleigh, 6th May 2024 – Shah
Capital Management, Inc. (together with its affiliates, “Shah Capital,” “we” or “our”) collectively
beneficially owns approximately 7.5% of the outstanding common stock of Novavax, Inc. (NASDAQ: NVAX) (“Novavax” or the “Company”),
making it a top three and largest non-index stockholder, today issued the below statement to stockholders regarding its intended
efforts at the 2024 Annual Meeting of Stockholders scheduled for Thursday, June 13, 2024, 8:30 a.m. Eastern Time (the “Annual Meeting”):
***
Fellow Novavax Stockholders:
Novavax’s upcoming Annual Meeting presents an
opportunity to send a strong and clear message to the Company’s board of directors (the “Board”) and management
– that stockholders cannot afford the status quo and the time for meaningful Board refreshment is now!
Shah Capital recognizes the critical importance of
effective board oversight and stewardship. Unfortunately, we have lost faith that the current directors have the ability or willingness
to adapt to market pressures and take the steps we believe are necessary to address its continuing dismal performance. As a result, Shah
Capital today filed a preliminary proxy statement to solicit stockholders to vote AGAINST the re-election of Richard
H. Douglas, Margaret G. McGlynn, and David Mott, each of the Company’s Class II Directors up for election at the
Annual Meeting. In our view, the Company’s current management has failed to implement effective strategies to turn the business
around despite its rapidly shrinking share price, necessitating material and immediate board refreshment. Novavax remains today one of
the most shorted stocks on NASDAQ.
The decision to launch this campaign follows our repeated
attempts to constructively engage with the Board. We strongly believe in the value of Novavax’s deep IP portfolio and Matrix-M
adjuvant platform and that there is a vast and currently untapped market for non-mRNA protein vaccines. We have offered several suggestions
to the Board aimed at addressing Novavax’s apparently self-inflicted problems, which we believe have significantly undermined its
growth and success. The Board regrettably has been unresponsive to our suggestions. Shah Capital has, therefore, decided to make its concerns
public and has today announced its intention to vote AGAINST the re-election of Mr. Douglas, Ms. McGlynn and Mr. Mott at the Annual
Meeting and urges Novavax stockholders to do the same.
Shah Capital further believes that the maintenance
and expansion of the Company’s generous compensation programs for its executive management and directors, given the Company’s
continuing poor performance and recent massive stockholder dilution is inappropriate. Therefore, Shah Capital is also calling on all Novavax
stockholders, as they assess the Company’s future direction and leadership, to vote AGAINST three of the Company’s other
proposals to be considered at the Annual Meeting, which include an advisory vote to approve the compensation of Novavax’s named
executive officers and amendments to certain of it’s compensation plans.
We believe that fresh perspectives are desperately
needed in the boardroom to steer Novavax towards sustainable profitable growth. Our campaign provides stockholders with an opportunity
to send a clear message to the Company that material change is needed now for the benefit of all stockholders. As a committed long-term
investor in Novavax, we have closely monitored the Company’s performance and governance practices and are Deeply Concerned by
the Company’s Shocking Destruction of Stockholder Value and the Market’s Apparent Lack of Faith in the Direction of the Company.
We reiterate our position that Novavax must urgently
adopt a more innovative and dynamic sales and marketing strategy. Specifically, that the Company should target key Covid segments in its
marketing, such as direct-to-patient outreach for individuals aged 60+ and residents of southern states, as well as develop more effective
regulatory stakeholder management, particularly with the FDA. Furthermore, we contend that Novavax should turn its Matrix-M adjuvant franchise’s
inactive pipeline candidates (such as Flu, RSV, and H5N1) into active opportunities through an infusion of outside capital and potential
strategic partnerships. Lastly, we believe efficient and effective spending is necessary for operational profitability at Novavax in 2024
and beyond.
We urge you to stand with us and vote AGAINST
the re-election of Mr. Douglas, Ms. McGlynn and Mr. Mott and AGAINST certain of the Company’s other proposals at the Annual
Meeting. By voting AGAINST each of the directors eligible for re-election, you will send a strong message to the Board that
you are dissatisfied with the status quo and believe urgent change is needed.
Under the Company’s policies, each of the directors
up for election at the Annual Meeting have already tendered an irrevocable contingent resignation to the Company’s secretary. Such
resignations will become effective, only if (i) such director fails to receive the requisite majority vote in an uncontested election
and (ii) accepted by the Board. In our view, if our campaign results in any director failing to receive a majority of the votes cast for
his or her election, then we believe it would clearly be inappropriate for any such director to continue to serve on the Board
and we would call on the Board to promptly accept his or her resignation.
We urge you to make your voice heard with your
“AGAINST VOTE.” Your action can help initiate the changes at Novavax that we believe are required to put Novavax on
a path towards success and sustained profitable growth.
Sincerely,
Shah Capital Management, Inc.
About Shah Capital:
Shah Capital is a global investment firm employing
a focused investment philosophy with an emphasis on turnarounds and special situations.
Media Contacts:
Citigate Dewe Rogerson
Shah Capital team |
shah@citigatedewerogerson.com |
Investors:
InvestorCom LLC
19 Old Kings Highway S. – Suite 130
Darien, CT 06820
Toll Free (877) 972-0090
Banks and Brokers call collect (203) 972-9300
shah@investor-com.com
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024